Overall, across all 11 PDXs regardless of the nature of the ATM alteration, AZD6738, AZD7648, and olaparib monotherapy treatments (at any dose level) all achieved a minimum best response of 50% tumour growth inhibition (TGI) in 4 out 11 models (36%) albeit the responses were not in the same models. This evidence concerns the gene ATM and neoplasm.